nodes	percent_of_prediction	percent_of_DWPC	metapath
Indapamide—KCNE1—ear—leprosy	0.11	0.347	CbGeAlD
Indapamide—KCNQ1—ear—leprosy	0.0505	0.159	CbGeAlD
Indapamide—KCNE1—eye—leprosy	0.0289	0.0914	CbGeAlD
Indapamide—Application site reaction—Dapsone—leprosy	0.0249	0.0365	CcSEcCtD
Indapamide—KCNE1—testis—leprosy	0.0159	0.0501	CbGeAlD
Indapamide—KCNE1—nervous system—leprosy	0.0156	0.0492	CbGeAlD
Indapamide—Electrolyte imbalance—Thalidomide—leprosy	0.0143	0.021	CcSEcCtD
Indapamide—CA4—nerve—leprosy	0.014	0.0443	CbGeAlD
Indapamide—Hernia—Thalidomide—leprosy	0.0128	0.0187	CcSEcCtD
Indapamide—Sinus bradycardia—Thalidomide—leprosy	0.0122	0.0179	CcSEcCtD
Indapamide—Myasthenia—Thalidomide—leprosy	0.00953	0.0139	CcSEcCtD
Indapamide—CA12—eye—leprosy	0.00948	0.0299	CbGeAlD
Indapamide—Oral candidiasis—Thalidomide—leprosy	0.00943	0.0138	CcSEcCtD
Indapamide—Nail disorder—Thalidomide—leprosy	0.00923	0.0135	CcSEcCtD
Indapamide—Tooth disorder—Thalidomide—leprosy	0.00923	0.0135	CcSEcCtD
Indapamide—Hypercalcaemia—Thalidomide—leprosy	0.00862	0.0126	CcSEcCtD
Indapamide—CA9—tendon—leprosy	0.00849	0.0268	CbGeAlD
Indapamide—Lung disorder—Thalidomide—leprosy	0.00846	0.0124	CcSEcCtD
Indapamide—Amblyopia—Thalidomide—leprosy	0.00776	0.0114	CcSEcCtD
Indapamide—Hyperaesthesia—Thalidomide—leprosy	0.00763	0.0112	CcSEcCtD
Indapamide—Nasopharyngitis—Dapsone—leprosy	0.00759	0.0111	CcSEcCtD
Indapamide—Muscular weakness—Dapsone—leprosy	0.00749	0.011	CcSEcCtD
Indapamide—Influenza—Dapsone—leprosy	0.00734	0.0107	CcSEcCtD
Indapamide—KCNQ1—testis—leprosy	0.00729	0.023	CbGeAlD
Indapamide—Pancreatitis—Dapsone—leprosy	0.0072	0.0105	CcSEcCtD
Indapamide—CA9—testis—leprosy	0.00703	0.0222	CbGeAlD
Indapamide—Vasodilation procedure—Thalidomide—leprosy	0.00682	0.00998	CcSEcCtD
Indapamide—Vasodilation—Thalidomide—leprosy	0.00682	0.00998	CcSEcCtD
Indapamide—Jaundice cholestatic—Thalidomide—leprosy	0.00682	0.00998	CcSEcCtD
Indapamide—Photosensitivity reaction—Dapsone—leprosy	0.0067	0.00981	CcSEcCtD
Indapamide—Bone disorder—Thalidomide—leprosy	0.00663	0.0097	CcSEcCtD
Indapamide—Arthropathy—Thalidomide—leprosy	0.00659	0.00964	CcSEcCtD
Indapamide—Oliguria—Thalidomide—leprosy	0.0065	0.00951	CcSEcCtD
Indapamide—Hyperuricaemia—Thalidomide—leprosy	0.00646	0.00945	CcSEcCtD
Indapamide—Drug interaction—Thalidomide—leprosy	0.00646	0.00945	CcSEcCtD
Indapamide—Bone pain—Thalidomide—leprosy	0.00625	0.00915	CcSEcCtD
Indapamide—Sinusitis—Dapsone—leprosy	0.00614	0.00899	CcSEcCtD
Indapamide—Blood uric acid increased—Thalidomide—leprosy	0.0061	0.00893	CcSEcCtD
Indapamide—Pharyngitis—Dapsone—leprosy	0.00583	0.00853	CcSEcCtD
Indapamide—Candida infection—Thalidomide—leprosy	0.00572	0.00837	CcSEcCtD
Indapamide—Blood urea increased—Thalidomide—leprosy	0.00565	0.00827	CcSEcCtD
Indapamide—CA5B—tendon—leprosy	0.00563	0.0178	CbGeAlD
Indapamide—Aplastic anaemia—Thalidomide—leprosy	0.00562	0.00823	CcSEcCtD
Indapamide—Tinnitus—Dapsone—leprosy	0.00548	0.00802	CcSEcCtD
Indapamide—Oesophagitis—Thalidomide—leprosy	0.00547	0.00801	CcSEcCtD
Indapamide—Lightheadedness—Thalidomide—leprosy	0.00536	0.00784	CcSEcCtD
Indapamide—Hypertonia—Thalidomide—leprosy	0.00525	0.00768	CcSEcCtD
Indapamide—Erythema—Dapsone—leprosy	0.00511	0.00748	CcSEcCtD
Indapamide—CA12—nervous system—leprosy	0.0051	0.0161	CbGeAlD
Indapamide—Diabetes mellitus—Thalidomide—leprosy	0.005	0.00731	CcSEcCtD
Indapamide—Photosensitivity—Thalidomide—leprosy	0.00495	0.00725	CcSEcCtD
Indapamide—Gastroenteritis—Thalidomide—leprosy	0.0049	0.00718	CcSEcCtD
Indapamide—CA2—eye—leprosy	0.00487	0.0154	CbGeAlD
Indapamide—Vascular purpura—Thalidomide—leprosy	0.00486	0.00711	CcSEcCtD
Indapamide—Vision blurred—Dapsone—leprosy	0.00482	0.00705	CcSEcCtD
Indapamide—Libido decreased—Thalidomide—leprosy	0.00469	0.00686	CcSEcCtD
Indapamide—CA5B—testis—leprosy	0.00466	0.0147	CbGeAlD
Indapamide—Increased appetite—Thalidomide—leprosy	0.00463	0.00677	CcSEcCtD
Indapamide—Amnesia—Thalidomide—leprosy	0.00463	0.00677	CcSEcCtD
Indapamide—Dermatitis exfoliative—Thalidomide—leprosy	0.00461	0.00674	CcSEcCtD
Indapamide—Vertigo—Dapsone—leprosy	0.00459	0.00672	CcSEcCtD
Indapamide—Visual disturbance—Thalidomide—leprosy	0.00459	0.00671	CcSEcCtD
Indapamide—Atrial fibrillation—Thalidomide—leprosy	0.00459	0.00671	CcSEcCtD
Indapamide—CA5B—nervous system—leprosy	0.00458	0.0144	CbGeAlD
Indapamide—Dermatitis bullous—Thalidomide—leprosy	0.00455	0.00666	CcSEcCtD
Indapamide—Purpura—Thalidomide—leprosy	0.00451	0.0066	CcSEcCtD
Indapamide—Arthritis—Thalidomide—leprosy	0.00447	0.00655	CcSEcCtD
Indapamide—Cough—Dapsone—leprosy	0.00446	0.00653	CcSEcCtD
Indapamide—Cerebrovascular accident—Thalidomide—leprosy	0.00444	0.00649	CcSEcCtD
Indapamide—Lethargy—Thalidomide—leprosy	0.00444	0.00649	CcSEcCtD
Indapamide—Hyponatraemia—Thalidomide—leprosy	0.00436	0.00639	CcSEcCtD
Indapamide—Osteoarthritis—Thalidomide—leprosy	0.00435	0.00636	CcSEcCtD
Indapamide—Disturbance in sexual arousal—Thalidomide—leprosy	0.00431	0.00631	CcSEcCtD
Indapamide—Migraine—Thalidomide—leprosy	0.00428	0.00626	CcSEcCtD
Indapamide—CA2—skin of body—leprosy	0.00423	0.0134	CbGeAlD
Indapamide—Face oedema—Thalidomide—leprosy	0.0042	0.00614	CcSEcCtD
Indapamide—Ataxia—Thalidomide—leprosy	0.00409	0.00598	CcSEcCtD
Indapamide—Tachycardia—Dapsone—leprosy	0.00407	0.00596	CcSEcCtD
Indapamide—Dehydration—Thalidomide—leprosy	0.00404	0.00592	CcSEcCtD
Indapamide—Liver function test abnormal—Thalidomide—leprosy	0.00401	0.00587	CcSEcCtD
Indapamide—Orthostatic hypotension—Thalidomide—leprosy	0.00397	0.00581	CcSEcCtD
Indapamide—Hypokalaemia—Thalidomide—leprosy	0.00396	0.00579	CcSEcCtD
Indapamide—Cramp muscle—Thalidomide—leprosy	0.00391	0.00573	CcSEcCtD
Indapamide—Toxic epidermal necrolysis—Thalidomide—leprosy	0.00391	0.00573	CcSEcCtD
Indapamide—CA4—tendon—leprosy	0.00389	0.0123	CbGeAlD
Indapamide—Muscular weakness—Thalidomide—leprosy	0.00383	0.00561	CcSEcCtD
Indapamide—Insomnia—Dapsone—leprosy	0.00377	0.00553	CcSEcCtD
Indapamide—Influenza—Thalidomide—leprosy	0.00376	0.0055	CcSEcCtD
Indapamide—Dysphagia—Thalidomide—leprosy	0.00376	0.0055	CcSEcCtD
Indapamide—Pancreatitis—Thalidomide—leprosy	0.00368	0.00539	CcSEcCtD
Indapamide—Angina pectoris—Thalidomide—leprosy	0.00366	0.00536	CcSEcCtD
Indapamide—Bronchitis—Thalidomide—leprosy	0.00361	0.00529	CcSEcCtD
Indapamide—Pollakiuria—Thalidomide—leprosy	0.00347	0.00508	CcSEcCtD
Indapamide—Erectile dysfunction—Thalidomide—leprosy	0.00346	0.00506	CcSEcCtD
Indapamide—Photosensitivity reaction—Thalidomide—leprosy	0.00343	0.00502	CcSEcCtD
Indapamide—Gastrointestinal pain—Dapsone—leprosy	0.00341	0.005	CcSEcCtD
Indapamide—Weight decreased—Thalidomide—leprosy	0.0034	0.00498	CcSEcCtD
Indapamide—Hyperglycaemia—Thalidomide—leprosy	0.00339	0.00496	CcSEcCtD
Indapamide—Pneumonia—Thalidomide—leprosy	0.00337	0.00493	CcSEcCtD
Indapamide—Drowsiness—Thalidomide—leprosy	0.00335	0.0049	CcSEcCtD
Indapamide—Depression—Thalidomide—leprosy	0.00334	0.00489	CcSEcCtD
Indapamide—Stevens-Johnson syndrome—Thalidomide—leprosy	0.00332	0.00486	CcSEcCtD
Indapamide—Abdominal pain—Dapsone—leprosy	0.0033	0.00483	CcSEcCtD
Indapamide—Body temperature increased—Dapsone—leprosy	0.0033	0.00483	CcSEcCtD
Indapamide—Renal failure—Thalidomide—leprosy	0.00329	0.00482	CcSEcCtD
Indapamide—Stomatitis—Thalidomide—leprosy	0.00327	0.00478	CcSEcCtD
Indapamide—Conjunctivitis—Thalidomide—leprosy	0.00326	0.00477	CcSEcCtD
Indapamide—CA2—tendon—leprosy	0.00322	0.0102	CbGeAlD
Indapamide—CA4—testis—leprosy	0.00322	0.0102	CbGeAlD
Indapamide—Sweating—Thalidomide—leprosy	0.00321	0.0047	CcSEcCtD
Indapamide—CA4—nervous system—leprosy	0.00316	0.00997	CbGeAlD
Indapamide—Sinusitis—Thalidomide—leprosy	0.00314	0.0046	CcSEcCtD
Indapamide—Agranulocytosis—Thalidomide—leprosy	0.00313	0.00458	CcSEcCtD
Indapamide—Rhinitis—Thalidomide—leprosy	0.00301	0.00441	CcSEcCtD
Indapamide—Hepatitis—Thalidomide—leprosy	0.00301	0.0044	CcSEcCtD
Indapamide—Hypoaesthesia—Thalidomide—leprosy	0.00299	0.00438	CcSEcCtD
Indapamide—Pharyngitis—Thalidomide—leprosy	0.00298	0.00437	CcSEcCtD
Indapamide—Urinary tract disorder—Thalidomide—leprosy	0.00297	0.00435	CcSEcCtD
Indapamide—Oedema peripheral—Thalidomide—leprosy	0.00296	0.00434	CcSEcCtD
Indapamide—Urethral disorder—Thalidomide—leprosy	0.00295	0.00431	CcSEcCtD
Indapamide—Visual impairment—Thalidomide—leprosy	0.0029	0.00424	CcSEcCtD
Indapamide—Erythema multiforme—Thalidomide—leprosy	0.00284	0.00416	CcSEcCtD
Indapamide—Tinnitus—Thalidomide—leprosy	0.0028	0.0041	CcSEcCtD
Indapamide—Cardiac disorder—Thalidomide—leprosy	0.00279	0.00408	CcSEcCtD
Indapamide—Arrhythmia—Thalidomide—leprosy	0.00269	0.00393	CcSEcCtD
Indapamide—CA2—testis—leprosy	0.00267	0.00842	CbGeAlD
Indapamide—Vomiting—Dapsone—leprosy	0.00265	0.00388	CcSEcCtD
Indapamide—CA2—nervous system—leprosy	0.00262	0.00827	CbGeAlD
Indapamide—Malnutrition—Thalidomide—leprosy	0.00262	0.00383	CcSEcCtD
Indapamide—Headache—Dapsone—leprosy	0.00261	0.00383	CcSEcCtD
Indapamide—Flatulence—Thalidomide—leprosy	0.00258	0.00378	CcSEcCtD
Indapamide—Tension—Thalidomide—leprosy	0.00257	0.00376	CcSEcCtD
Indapamide—Dysgeusia—Thalidomide—leprosy	0.00256	0.00375	CcSEcCtD
Indapamide—Nervousness—Thalidomide—leprosy	0.00254	0.00372	CcSEcCtD
Indapamide—Back pain—Thalidomide—leprosy	0.00253	0.00371	CcSEcCtD
Indapamide—Muscle spasms—Thalidomide—leprosy	0.00252	0.00368	CcSEcCtD
Indapamide—Nausea—Dapsone—leprosy	0.00248	0.00363	CcSEcCtD
Indapamide—Vision blurred—Thalidomide—leprosy	0.00247	0.00361	CcSEcCtD
Indapamide—Ill-defined disorder—Thalidomide—leprosy	0.00243	0.00356	CcSEcCtD
Indapamide—Anaemia—Thalidomide—leprosy	0.00242	0.00354	CcSEcCtD
Indapamide—Agitation—Thalidomide—leprosy	0.00241	0.00352	CcSEcCtD
Indapamide—Angioedema—Thalidomide—leprosy	0.00239	0.0035	CcSEcCtD
Indapamide—Malaise—Thalidomide—leprosy	0.00236	0.00346	CcSEcCtD
Indapamide—Vertigo—Thalidomide—leprosy	0.00235	0.00344	CcSEcCtD
Indapamide—Syncope—Thalidomide—leprosy	0.00235	0.00344	CcSEcCtD
Indapamide—Leukopenia—Thalidomide—leprosy	0.00234	0.00343	CcSEcCtD
Indapamide—Palpitations—Thalidomide—leprosy	0.00231	0.00339	CcSEcCtD
Indapamide—Loss of consciousness—Thalidomide—leprosy	0.0023	0.00337	CcSEcCtD
Indapamide—Cough—Thalidomide—leprosy	0.00228	0.00334	CcSEcCtD
Indapamide—Arthralgia—Thalidomide—leprosy	0.00223	0.00326	CcSEcCtD
Indapamide—Chest pain—Thalidomide—leprosy	0.00223	0.00326	CcSEcCtD
Indapamide—Myalgia—Thalidomide—leprosy	0.00223	0.00326	CcSEcCtD
Indapamide—Anxiety—Thalidomide—leprosy	0.00222	0.00325	CcSEcCtD
Indapamide—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.00221	0.00324	CcSEcCtD
Indapamide—Discomfort—Thalidomide—leprosy	0.0022	0.00322	CcSEcCtD
Indapamide—Dry mouth—Thalidomide—leprosy	0.00218	0.00319	CcSEcCtD
Indapamide—Oedema—Thalidomide—leprosy	0.00214	0.00313	CcSEcCtD
Indapamide—Infection—Thalidomide—leprosy	0.00212	0.00311	CcSEcCtD
Indapamide—Shock—Thalidomide—leprosy	0.0021	0.00308	CcSEcCtD
Indapamide—Nervous system disorder—Thalidomide—leprosy	0.0021	0.00307	CcSEcCtD
Indapamide—Thrombocytopenia—Thalidomide—leprosy	0.00209	0.00306	CcSEcCtD
Indapamide—Tachycardia—Thalidomide—leprosy	0.00209	0.00305	CcSEcCtD
Indapamide—Skin disorder—Thalidomide—leprosy	0.00208	0.00304	CcSEcCtD
Indapamide—Hyperhidrosis—Thalidomide—leprosy	0.00207	0.00302	CcSEcCtD
Indapamide—Anorexia—Thalidomide—leprosy	0.00204	0.00298	CcSEcCtD
Indapamide—Hypotension—Thalidomide—leprosy	0.002	0.00292	CcSEcCtD
Indapamide—Musculoskeletal discomfort—Thalidomide—leprosy	0.00195	0.00285	CcSEcCtD
Indapamide—Insomnia—Thalidomide—leprosy	0.00193	0.00283	CcSEcCtD
Indapamide—Paraesthesia—Thalidomide—leprosy	0.00192	0.00281	CcSEcCtD
Indapamide—Dyspnoea—Thalidomide—leprosy	0.0019	0.00279	CcSEcCtD
Indapamide—Somnolence—Thalidomide—leprosy	0.0019	0.00278	CcSEcCtD
Indapamide—Dyspepsia—Thalidomide—leprosy	0.00188	0.00275	CcSEcCtD
Indapamide—Decreased appetite—Thalidomide—leprosy	0.00186	0.00272	CcSEcCtD
Indapamide—Gastrointestinal disorder—Thalidomide—leprosy	0.00184	0.0027	CcSEcCtD
Indapamide—Fatigue—Thalidomide—leprosy	0.00184	0.0027	CcSEcCtD
Indapamide—Pain—Thalidomide—leprosy	0.00183	0.00267	CcSEcCtD
Indapamide—Constipation—Thalidomide—leprosy	0.00183	0.00267	CcSEcCtD
Indapamide—Feeling abnormal—Thalidomide—leprosy	0.00176	0.00258	CcSEcCtD
Indapamide—Gastrointestinal pain—Thalidomide—leprosy	0.00175	0.00256	CcSEcCtD
Indapamide—Urticaria—Thalidomide—leprosy	0.0017	0.00248	CcSEcCtD
Indapamide—CYP3A4—nervous system—leprosy	0.00169	0.00533	CbGeAlD
Indapamide—Body temperature increased—Thalidomide—leprosy	0.00169	0.00247	CcSEcCtD
Indapamide—Abdominal pain—Thalidomide—leprosy	0.00169	0.00247	CcSEcCtD
Indapamide—Hypersensitivity—Thalidomide—leprosy	0.00157	0.0023	CcSEcCtD
Indapamide—Asthenia—Thalidomide—leprosy	0.00153	0.00224	CcSEcCtD
Indapamide—Pruritus—Thalidomide—leprosy	0.00151	0.00221	CcSEcCtD
Indapamide—Diarrhoea—Thalidomide—leprosy	0.00146	0.00214	CcSEcCtD
Indapamide—Dizziness—Thalidomide—leprosy	0.00141	0.00207	CcSEcCtD
Indapamide—Vomiting—Thalidomide—leprosy	0.00136	0.00199	CcSEcCtD
Indapamide—Rash—Thalidomide—leprosy	0.00135	0.00197	CcSEcCtD
Indapamide—Dermatitis—Thalidomide—leprosy	0.00135	0.00197	CcSEcCtD
Indapamide—Headache—Thalidomide—leprosy	0.00134	0.00196	CcSEcCtD
Indapamide—Nausea—Thalidomide—leprosy	0.00127	0.00186	CcSEcCtD
